RecruitingPhase 1NCT07783477
A Study of Armored CAR T Cells in People With Cancer
A Phase I Trial for R/R MetAstatic DLL3+ Cancers Utilizing Armored CAR T Cells (ARMADA)
Sponsor
Memorial Sloan Kettering Cancer Center
Enrollment
16 participants
Start Date
Aug 28, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to test the safety of DLL3-SAVVYZ-IL18 in people with DLL3+ cancer.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This clinical trial is studying a drug called DLL3-SAVVYZ-IL18 CAR T cell for people with neuroendocrine cancer, small cell lung cancer, and other related conditions. The study is currently recruiting participants at 7 locations. People eligible for this study include aged 18 Years and older.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGDLL3-SAVVYZ-IL18 CAR T cell
DLL3-SAVVYZ-IL18 CAR T cell
Locations(7)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07783477
Related Trials
Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)
NCT07778316
Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors
NCT021461701 location
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
NCT07625644
Prospective Study of Intensity-Modulated Proton Therapy (IMPT) for Small Cell Lung Cancer
NCT043424291 location
Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors
NCT0708024220 locations